News | July 19, 2011

German Patient Surpasses 5 Years of Support on DuraHeart Left Ventricular Assist Device

July 19, 2011 — Terumo Heart Inc., a wholly owned subsidiary of Terumo Corp., announced that a patient implanted with the DuraHeart left ventricular assist system (LVAS) has surpassed five years of support on the mechanical circulatory support device. Helga Gieseke, living in Germany, was treated at The Deutsches Herzzentrum Berlin (DHZB, German Heart Institute Berlin) and is now one of the longest-living heart failure recipients of the DuraHeart LVAS device.

"Now I can breathe again,” she said. “For years before I received the DuraHeart I was unable to do anything with my children or grandchildren. Since the DuraHeart, I was able to experience the birth of my little grandchild. I can now do things like walk and play catch and am able to participate in the lives of my family."

Gieseke's heart problems have been occurring since the 1980s; her first heart surgery was performed in 1994. Between 1994 and 2006, she underwent several procedures including implantation of stents, pacemakers and implantable defibrillators in an attempt to manage her condition. Despite all these treatments, Mrs. Gieseke's condition continued to deteriorate until she found herself unable to walk or carry out simple activities without experiencing chest pain and being short of breath.

Gieseke admits that without the DuraHeart, she would probably not have lived to see her most recent birthday. "DuraHeart was my only option; there is a shortage of donor organs, and DuraHeart was my last chance. My family supported my decision [to implant an investigational device] and we have all been extremely happy with the decision and the quality of life the DuraHeart has afforded me."

The system is the latest-generation rotary blood pump designed for long-term patient support. The system incorporates a centrifugal flow rotary pump with the magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single contact point. The impeller's active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The DuraHeart carries a CE mark and is currently available for sale in Japan and Europe. It is limited to investigational use only in the United States.

For more information: www.terumoheart.com
 

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...